Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biophytis ( (BPTSY) ) just unveiled an update.
On September 2, 2025, Biophytis announced it received authorization from the European Medicines Agency to commence a Phase 2 clinical trial for its drug candidate BIO101, targeting muscle wasting associated with obesity. This approval marks a significant regulatory milestone for Biophytis, enhancing its clinical development strategy in Europe. The company plans to initiate patient recruitment soon and is also preparing to expand its trial efforts to Brazil, following interactions with the Brazilian Health Regulatory Agency.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is being developed for muscular diseases such as sarcopenia and metabolic disorders like obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis is publicly traded on Euronext Growth Paris and the OTC market.
Technical Sentiment Signal: Sell
Current Market Cap: $4.9M
Find detailed analytics on BPTSY stock on TipRanks’ Stock Analysis page.